In a malaria‑negative adult patient with fever, cytopenias, markedly elevated ferritin and suspected hemophagocytic lymphohistiocytosis, what is the appropriate diagnostic work‑up and acute management, including ICU admission, broad‑spectrum antibiotics, fluid resuscitation, and HLH‑specific therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hemophagocytic Lymphohistiocytosis (HLH) in Malaria-Negative Febrile Adult

In a malaria-negative adult with fever, cytopenias, and markedly elevated ferritin suspicious for HLH, immediately initiate diagnostic workup using HLH-2004 criteria while simultaneously starting high-dose corticosteroids (dexamethasone 10 mg/m² or methylprednisolone 1 g/day for 3-5 days) if 5 of 8 criteria are met or clinical suspicion is high, and aggressively search for the underlying trigger—infection, malignancy, or autoimmune disease—as this determines definitive management. 1

Diagnostic Workup

Immediate Laboratory Assessment

Apply the HLH-2004 criteria (need 5 of 8) 1:

  • Fever (often present)
  • Cytopenias affecting ≥2 lineages: Hemoglobin <90 g/L, platelets <100×10⁹/L, neutrophils <1.0×10⁹/L
  • Ferritin ≥500 μg/L (but >7,000-10,000 μg/L is highly suggestive in adults; >10,000 μg/L raises specificity to ~90% though less than in pediatrics) 1
  • Hypertriglyceridemia (≥3.0 mmol/L) and/or hypofibrinogenemia (≤1.5 g/L)
  • Splenomegaly (clinical or imaging)
  • Hemophagocytosis in bone marrow, spleen, or lymph nodes (absence does not exclude HLH)
  • Low/absent NK cell activity (if available)
  • Elevated soluble CD25 (sCD25) ≥2,400 U/mL

Critical point: Hyperferritinemia >10,000 μg/L should immediately trigger HLH evaluation, though this threshold is less specific in adults than children 1. The HScore ≥169 provides 82-95% sensitivity and 60-94% specificity for adult HLH 2, 3.

Mandatory Trigger Search (Must Continue Despite Treatment)

Infections (most common in adults, 42.5% of ICU cases) 1, 4:

  • EBV serology and DNA PCR (>10³ copies/mL significant) 1
  • HIV, CMV, influenza testing
  • Blood cultures (repeat if initially negative)
  • Consider Leishmania, rickettsial disease, tuberculosis based on exposure

Malignancies (40-70% of adult HLH, particularly with age) 1:

  • Lymphomas are the dominant cause: T-cell/NK-cell (35%), B-cell (32%), Hodgkin (6%)
  • PET-CT imaging to detect occult lymphoma 1, 5
  • Bone marrow biopsy (essential—may reveal hemophagocytosis AND underlying malignancy) 1, 5
  • Elevated sCD25/ferritin ratio suggests lymphoma-associated HLH 1
  • Consider splenectomy if splenomegaly with unknown cause (lymphoma may hide in spleen) 1

Autoimmune triggers (if history of Still's disease, lupus, vasculitis) 1

Genetic Testing

Consider in young adults, family history of consanguinity/HLH, recurrent disease, or unknown trigger—but do not delay treatment pending results 1. Hypomorphic mutations (e.g., PRF1 A91V) found in 7-25% of adults but present in 10% of healthy individuals 1.

Acute Management Algorithm

Step 1: ICU Admission and Supportive Care

  • ICU admission is appropriate given multiorgan dysfunction risk and mortality of 20-88% (60% in ICU cohorts, 71% in malignancy-associated HLH) 1, 4
  • Broad-spectrum antibiotics are essential—secondary infections are a major cause of death 1
  • Fluid resuscitation per standard sepsis protocols (HLH often mimics sepsis; both can coexist) 1
  • Antimicrobial prophylaxis: Pneumocystis jirovecii, fungal, and antiviral prophylaxis due to severe T-cell depletion from disease and treatment 1

Step 2: Immediate HLH-Specific Therapy

For severe HLH with organ failure or rapid deterioration 1:

  • Dexamethasone 10 mg/m² daily OR methylprednisolone 1 g/day for 3-5 days (pulse dosing) 1
  • Etoposide 150 mg/m² (reduce to 50-100 mg/m² in elderly/comorbid patients; reduce dose in renal impairment, NOT for isolated liver dysfunction) 1
    • Etoposide frequency: once weekly instead of twice weekly in adults 1
    • Immediate etoposide indicated for imminent organ failure or rapid deterioration 1
  • IVIG 1.6 g/kg over 2-3 days (anti-inflammatory effects) 1

For less severe or improving disease 1:

  • Short course of corticosteroids alone (with/without IVIG)
  • Weekly reevaluation for need to escalate to etoposide 1

For MAS-HLH (autoimmune background) 1, 6:

  • High-dose methylprednisolone (1 g/day × 3-5 days) first-line
  • Add cyclosporine A (2-7 mg/kg/day) if insufficient response
  • Anakinra (IL-1 blockade): 2-10 mg/kg/day subcutaneously in divided doses 1
  • Consider tocilizumab (IL-6 blockade) 1

Step 3: Trigger-Specific Modifications

EBV-HLH 1:

  • Add rituximab 375 mg/m² weekly × 2-4 doses (targets B-cell EBV reservoir)
  • Monitor EBV DNA, ferritin, sCD25 to guide rituximab duration
  • Note: Rituximab does NOT replace corticosteroids/etoposide (EBV also infects T/NK cells)

Malignancy-associated HLH 1, 5:

  • Treat the underlying malignancy (e.g., R-CHOP for lymphoma)—this is definitive therapy
  • Corticosteroids/anakinra provide temporary control only
  • Etoposide use is controversial; prioritize cancer-directed therapy

Infection-associated HLH (Leishmania, rickettsial, TB) 1:

  • Pathogen-specific antimicrobials are primary treatment
  • Avoid HLH-94 immunosuppression in these cases (responds to antimicrobials alone)

HIV-HLH 1:

  • Initiate highly active antiretroviral therapy
  • Short course corticosteroids ± IVIG
  • Etoposide used in ~50% of cases

Step 4: Monitoring and Duration

  • Weekly reassessment of need for continued etoposide (many require 8 weeks) 1
  • Monitor ferritin (failure to decrease predicts mortality; minimum >4,083 μg/L post-diagnosis predicts 30-day mortality with 94% sensitivity) 4
  • Track sCD25, cell counts, triglycerides, fibrinogen
  • Ferritin >10,000 μg/L after treatment initiation is highly predictive of poor outcome 4

Critical Pitfalls to Avoid

  1. Delaying treatment while awaiting bone marrow biopsy—start therapy if clinical suspicion is high even without meeting all 5 criteria 1

  2. Assuming hyperferritinemia >10,000 μg/L is 90% specific in adults—this is pediatric data; adult specificity is lower, requiring integration of other criteria 1, 2

  3. Using immunosuppression for pathogen-specific HLH (Leishmania, rickettsial, TB)—these respond to antimicrobials alone 1

  4. Stopping trigger search after starting treatment—continue investigating for occult malignancy throughout treatment course 1

  5. Treating malignancy-associated HLH with immunosuppression alone—definitive treatment requires addressing the underlying cancer 1, 5

  6. Overlooking secondary infections—these cause major mortality; maintain broad antimicrobial prophylaxis 1

  7. Confusing "HLH during chemotherapy" with malignancy-triggered HLH—the former is usually infection-induced and requires different management (corticosteroids ± IVIG, spare etoposide to allow marrow recovery) 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.